To learn more about this report, Within the global anti-obesity drug market segmented by drug class, GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists hold the highest share with an estimated 23.1% in 2026, driven largely by their dual role in appetite regulation and glucose metabolism
Demand for precision medicine has propelled research activities, contributing to steady expansion across global pharmaceutical and biotechnology sectors
60 Medical questionnaire Structured digital history covering family, lifestyle, symptoms and longevity goals
An important aspect of the study design was the inclusion of clinically non-epileptic children with abnormal EEG findings
GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have produced some of the most dramatic weight loss outcomes in the history of pharmacology
The most valuable property of the orobuccal mucosa is that drugs that can be absorbed, enter the systemic circulation directly by passive transport
